Incyte Tumbles On More Jakafi Trial Terminations
This article was originally published in Scrip
Executive Summary
Incyte Corporation is discontinuing all ongoing trials for its Janus kinase inhibitor, Jakafi (ruxolitinib), in solid tumors following poor results in a Phase III study in metastatic pancreatic cancer and in a recently suspended Phase II colorectal cancer trial.